Organon & Co. (OGN) to Issue Quarterly Dividend of $0.02 on December 10th

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Friday, October 30th. Shareholders of record on Monday, November 9th will be paid a dividend of $0.02 per share on Thursday, December 10th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, November 9th.

Organon & Co. has a dividend payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $3.43 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Price Performance

Organon & Co. stock opened at $13.84 on Friday. The firm’s 50-day moving average is $13.75 and its two-hundred day moving average is $11.60. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.02 and a quick ratio of 1.44. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.88. The stock has a market capitalization of $3.63 billion, a P/E ratio of 18.20, a P/E/G ratio of 1.27 and a beta of 1.53.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.06. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. Equities analysts predict that Organon & Co. will post 3.24 earnings per share for the current year.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.